(Q22122087)

Dimensions Publication ID

Dimensions

1041997045

6 February 2023

Robert F Reilly

series ordinal

2

author given names

Robert F

author last names

Reilly

1 reference

Dimensions Publication ID

Dimensions

1041997045

Nature Clinical Practice Nephrology

6 February 2023

language of work or name

English

0 references

publication date

December 2007

0 references

published in

0 references

volume

3

0 references

issue

12

0 references

page(s)

654-668

0 references

cites work

Gadolinium-based contrast agents as an alternative at vena cavography in patients with renal insufficiency--early experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

Renal insufficiency: usefulness of gadodiamide-enhanced renal angiography to supplement CO2-enhanced renal angiography for diagnosis and percutaneous treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

Gadolinium-containing contrast media for radiographic examinations: a position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

Gd-DOTA: characterization of a new paramagnetic complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

MS-325: albumin-targeted contrast agent for MR angiography

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Gadobenate dimeglumine (Gd-BOPTA). An overview

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

The relationship between thermodynamics and the toxicity of gadolinium complexes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrotoxicity of high-dose gadolinium compared with iodinated contrast

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Gadodiamide as an alternative contrast agent in intravenous digital subtraction angiography and interventional procedures of the upper extremity veins

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

The safety of gadolinium in patients with stage 3 and 4 renal failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Safety of gadolinium contrast angiography in patients with chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Scleromyxoedema-like cutaneous diseases in renal-dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Safety of Gadolinium Contrast Agent in Hemodialysis Patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrogenic systemic fibrosis: risk factors and incidence estimation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Case-control study of gadodiamide-related nephrogenic systemic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Gadolinium deposition in nephrogenic fibrosing dermopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrogenic fibrosing dermopathy in pediatric patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

MDRD equations for estimation of GFR in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Poor prediction of the glomerular filtration rate using current formulas in de novo liver transplant patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrogenic fibrosing dermopathy: the first 6 years

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy)

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Scleromyxoedema-like changes in four renal dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrogenic fibrosing dermopathy with systemic involvement

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

A variant of nephrogenic fibrosing dermopathy with osteoclast-like giant cells: a syndrome of dysregulated matrix remodeling?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Osseous metaplasia in the setting of nephrogenic fibrosing dermopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

UV-A1 phototherapy improves nephrogenic fibrosing dermopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrogenic Systemic Fibrosis: A Mysterious Disease in Patients with Renal Failure--Role of Gadolinium-Based Contrast Media in Causation and the Beneficial Effect of Intravenous Sodium Thiosulfate

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Clearance of gadolinium chelates by hemodialysis: an in vitro study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Effect of the surface potential of the hemodialysis membrane and the electrical charge of the gadolinium contrast medium on dialyzability

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Dialyzability of gadodiamide in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Pharmacokinetics of Gd-DTPA in Patients with Chronic Renal Failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Permeability of iodinated and MR contrast media through two types of hemodialysis membrane

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Permeability of gadolinium-DTPA through two types of hemodialysis membrane

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Gadodiamide administration causes spurious hypocalcemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

ACR Guidance Document for Safe MR Practices: 2007

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Commentary on "ACR guidance document for safe MR practices: 2007"

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021

Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0660

7 January 2021